The Cureus Journal of Medical ScienceCardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic ReviewType 2 diabetes (T2DM) management increasingly focuses on cardiometabolic protection. Sodium-glucose co-transporter-2 inhibitors (SGLT2is)….1 day ago